• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
10 Truveta Research insights & publications of 2023

10 Truveta Research insights & publications of 2023

by Truveta staff | Dec 15, 2023 | Research

As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Truveta Research | Nov 27, 2023 | Research, Research Insights

Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...
Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023

Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023

by Truveta staff | Nov 21, 2023 | Data

ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
Next Entries »

Share this


Recent posts

  • FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents
  • ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer
  • ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice